Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.28 Insider Own42.92% Shs Outstand48.30M Perf Week-6.45%
Market Cap141.38M Forward P/E- EPS next Y-1.15 Insider Trans4.94% Shs Float27.00M Perf Month83.54%
Income-61.76M PEG- EPS next Q-0.33 Inst Own36.96% Short Float / Ratio3.59% / 2.02 Perf Quarter-55.66%
Sales82.85M P/S1.71 EPS this Y30.55% Inst Trans-2.95% Short Interest0.97M Perf Half Y-61.44%
Book/sh2.63 P/B1.10 EPS next Y8.20% ROA-30.74% Target Price2.58 Perf Year-74.04%
Cash/sh2.96 P/C0.98 EPS next 5Y- ROE-41.17% 52W Range1.04 - 15.30 Perf YTD-76.25%
Dividend- P/FCF- EPS past 5Y-55.84% ROI-38.40% 52W High-81.04% Beta2.65
Dividend %- Quick Ratio11.47 Sales past 5Y87.82% Gross Margin84.58% 52W Low178.85% ATR0.34
Employees250 Current Ratio12.11 Sales Q/Q7.13% Oper. Margin-76.31% RSI (14)52.34 Volatility11.20% 13.62%
OptionableYes Debt/Eq0.27 EPS Q/Q42.28% Profit Margin-74.55% Rel Volume1.14 Prev Close3.41
ShortableYes LT Debt/Eq0.27 EarningsNov 07 AMC Payout- Avg Volume480.65K Price2.90
Recom2.67 SMA2022.38% SMA500.00% SMA200-59.06% Volume547,102 Change-14.96%
Date Action Analyst Rating Change Price Target Change
Sep-12-23Downgrade William Blair Outperform → Mkt Perform
Sep-12-23Downgrade Piper Sandler Overweight → Neutral $15 → $5.50
Sep-12-23Downgrade BofA Securities Neutral → Underperform $10 → $4.50
Aug-24-23Downgrade Morgan Stanley Overweight → Equal-Weight $12 → $8.40
Jul-10-23Downgrade Citigroup Buy → Neutral $15 → $9
Jan-06-23Upgrade Stifel Hold → Buy $10 → $15
Oct-04-22Initiated Needham Hold
Jul-26-22Initiated Stifel Hold $10
Feb-03-22Initiated William Blair Outperform
Jan-07-22Upgrade Morgan Stanley Equal-Weight → Overweight $36 → $27
Nov-13-23 03:40PM
Nov-12-23 09:40AM
Nov-07-23 04:05PM
Oct-26-23 05:30PM
Oct-24-23 04:05PM
04:05PM Loading…
Oct-19-23 04:05PM
Oct-12-23 04:05PM
Oct-03-23 08:30AM
Sep-12-23 09:53AM
Sep-11-23 04:06PM
Aug-30-23 04:05PM
Aug-03-23 06:35PM
09:55AM Loading…
Jul-24-23 09:55AM
Jul-20-23 04:05PM
Jul-17-23 12:00PM
Jun-21-23 08:30AM
Jun-09-23 04:05PM
May-23-23 08:30AM
May-09-23 09:55AM
May-06-23 11:30AM
May-04-23 06:45PM
May-01-23 04:05PM
Apr-26-23 04:05PM
Apr-20-23 04:05PM
Apr-19-23 01:57PM
04:05PM Loading…
Apr-13-23 04:05PM
Apr-11-23 05:22AM
Apr-03-23 04:05PM
Mar-30-23 08:00AM
Mar-23-23 11:25AM
Mar-14-23 11:22AM
Mar-13-23 05:25PM
Mar-09-23 08:30AM
Feb-23-23 04:05PM
Feb-22-23 04:05PM
Feb-14-23 07:10AM
Jan-26-23 08:30AM
Jan-09-23 04:20PM
Jan-04-23 10:00AM
Dec-29-22 09:10AM
Dec-13-22 01:09PM
Dec-08-22 08:30AM
Nov-22-22 08:30AM
Nov-16-22 05:21AM
Nov-10-22 05:35PM
Nov-03-22 10:00AM
Oct-20-22 05:20PM
Oct-14-22 10:51AM
Oct-04-22 03:38PM
Sep-29-22 08:30AM
Sep-28-22 08:30AM
Sep-16-22 08:00AM
Sep-13-22 03:01AM
Sep-02-22 08:00AM
Aug-25-22 04:05PM
Aug-23-22 08:03AM
Aug-16-22 12:23PM
Aug-12-22 02:31AM
Aug-11-22 04:05PM
Aug-10-22 10:25AM
Aug-09-22 09:55AM
Aug-04-22 10:00AM
Aug-02-22 09:55AM
Jul-29-22 08:48AM
Jul-28-22 08:00AM
Jul-19-22 04:26PM
Jul-18-22 09:55AM
Jul-06-22 01:55PM
May-31-22 08:00AM
May-19-22 08:00AM
May-10-22 04:05PM
May-07-22 10:40AM
Apr-29-22 08:00AM
Apr-20-22 04:05PM
Apr-14-22 04:05PM
Mar-26-22 02:31PM
Mar-25-22 07:08AM
Mar-24-22 04:05PM
Mar-16-22 08:00AM
Mar-03-22 04:05PM
Mar-02-22 08:00AM
Feb-28-22 07:53AM
Feb-21-22 04:05PM
Feb-18-22 11:41AM
Feb-17-22 08:00AM
Feb-08-22 08:34AM
Jan-13-22 08:54AM
Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Encrantz StaffanDirectorNov 30Buy3.46140,777486,6381,012,150Dec 01 07:39 PM
Encrantz StaffanDirectorNov 29Buy3.503,22311,280871,373Dec 01 07:39 PM
Encrantz StaffanDirectorNov 28Buy3.46253,669877,137868,150Nov 28 08:32 PM
Encrantz StaffanDirectorNov 27Buy3.31246,331815,947614,481Nov 28 08:32 PM
Badawi DavidChief Technology OfficerNov 24Option Exercise0.11150,00016,5001,631,196Nov 28 08:16 PM
Encrantz StaffanDirectorNov 24Buy3.0921,85567,427368,150Nov 28 08:32 PM
Encrantz StaffanDirectorNov 22Buy2.5041,085102,708346,295Nov 22 06:19 PM
Encrantz StaffanDirectorNov 21Buy2.4868,477169,535305,210Nov 22 06:19 PM
Encrantz StaffanDirectorNov 20Buy2.2579,234178,189236,733Nov 22 06:19 PM
Encrantz StaffanDirectorNov 17Buy2.19126,664277,293157,499Nov 20 09:45 PM
Encrantz StaffanDirectorNov 16Buy2.0033967830,835Nov 20 09:45 PM
Encrantz StaffanDirectorNov 14Buy2.003,4626,91430,496Nov 16 05:44 PM
Park Sam BoongChief Operating OfficerSep 14Option Exercise1.9637,66873,82989,092Sep 15 06:33 PM